Cost-Effectiveness of the INTERCEPT Blood System

for Platelets 

Many countries have approved incremental reimbursement for pathogen-inactivated platelets, including Switzerland and Belgium. In addition, the INTERCEPT™ Blood System for platelets allows hospitals to save costs by:

  • Reducing the frequency of adverse events
  • Reducing the need to transfuse expensive single donor platelets
  • Eliminating the need for gamma-irradiated platelets
  • Eliminating the need to purchase CMV negative platelets
  • Not having to introduce secondary point of release testing

In the US reimbursement for outpatient hospital billing of pathogen-reduced platelets has been approved in 2015.